Targeting tumor-associated carbonic anhydrase IX in cancer therapy

Trends in Pharmacological Sciences

Volumn 27, Issue 11, 2006, Pages 566-573

  Thiry, Anne ^a   Dogné, Jean Michel ^a   Masereel, Bernard ^a   Supuran, Claudiu T ^b  

^a UNIVERSITY OF NAMUR   (Belgium)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE INHIBITOR; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1; INDISULAM; MELPHALAN; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COLON CANCER; DUODENUM CANCER; ENDOMETRIUM CANCER; ENZYME ACTIVE SITE; ENZYME STRUCTURE; ESOPHAGUS CANCER; GALLBLADDER CANCER; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; METASTASIS INHIBITION; NONHUMAN; PANCREAS CANCER; PH; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RESPIRATORY TRACT CANCER; SALIVARY GLAND CANCER; SKIN CANCER; SOLID TUMOR; STOMACH CANCER; STRUCTURE ANALYSIS; TESTIS CANCER; TUMOR CELL; UTERINE CERVIX CANCER;

ANIMALS; ANOXIA; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CATALYTIC DOMAIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASMS; PROTEIN CONFORMATION; SULFONAMIDES;

EID: 33750082400     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.09.002     Document Type: Article

References (48)

1. Supuran C.T. Carbonic anhydrases: catalytic and inhibition mechanisms, distribution and physiological roles. In: Supuran C.T., et al. (Ed). Carbonic Anhydrase. Its Inhibitors and Activators (2004), CRC Press 1-23
2. Hilvo M., et al. Characterization of CA XV, a new GPI-anchored form of carbonic anhydrase. Biochem. J. 392 (2005) 83-92
3. Pastoreková S., and Pastorek J. Cancer-related carbonic anhydrase isozymes and their inhibition. In: Supuran C.T., et al. (Ed). Carbonic Anhydrase. Its Inhibitors and Activators (2004), CRC Press 255-281
4. Tureci O., et al. Human carbonic anhydrase XII: cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 7608-7613
5. Pastorekova S., et al. A novel quasi-viral agent, MaTu, is a two-component system. Virology 187 (1992) 620-626
6. Alvarez B.V., et al. Metabolon disruption: a mechanism that regulates bicarbonate transport. EMBO J. 24 (2005) 2499-2511
7. Hockel M., and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93 (2001) 266-276
8. Wykoff C.C., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60 (2000) 7075-7083
9. Pastorekova S., et al. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J. Enzyme Inhib. Med. Chem. 19 (2004) 199-229
10. Loncaster J.A., et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 61 (2001) 6394-6399
11. Bartosova M., et al. Expression of carbonic anhydrase IX in breast is associated with malignant tissues and is related to overexpression of c-erbB2. J. Pathol. 197 (2002) 314-321
12. Ivanov S., et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 158 (2001) 905-919
13. Saarnio J., et al. Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumours. J. Hepatol. 35 (2001) 643-649
14. Kivela A.J., et al. Expression of transmembrane carbonic anhydrase isoenzymes IX and XII in normal human pancreas and pancreatic tumours. Histochem. Cell Biol. 114 (2000) 197-204
15. Vermylen P., et al. Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. Eur. Respir. J. 14 (1999) 806-811
16. Saarnio J., et al. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am. J. Pathol. 153 (1998) 279-285
17. Turner J.R., et al. MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker. Hum. Pathol. 28 (1997) 740-744
18. McKiernan J.M., et al. Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res. 57 (1997) 2362-2365
19. Liao S.Y., et al. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 57 (1997) 2827-2831
20. Leppilampi M., et al. Carbonic anhydrase isozymes IX and XII in gastric tumors. World J. Gastroenterol. 9 (2003) 1398-1403
21. Mekhail K., et al. HIF activation by pH-dependent nucleolar sequestration of VHL. Nat. Cell Biol. 6 (2004) 642-647
22. Zavada J., et al. Human tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion. Br. J. Cancer 82 (2000) 1808-1813
23. Svastova E., et al. Carbonic anhydrase IX reduces E-cadherin-mediated adhesion of MDCK cells via interaction with β-catenin. Exp. Cell Res. 290 (2003) 332-345
24. Opavsky R., et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 33 (1996) 480-487
25. Supuran C.T., et al. Carbonic anhydrase inhibitors. Med. Res. Rev. 23 (2003) 146-189
26. Ashida S., et al. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. J. Cancer Res. Clin. Oncol. 128 (2002) 561-568
27. Svastova E., et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 577 (2004) 439-445
28. Helmlinger G., et al. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin. Cancer Res. 8 (2002) 1284-1291
29. Stubbs M., et al. Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today 6 (2000) 15-19
30. Robertson N., et al. Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Res. 64 (2004) 6160-6165
31. Supuran C.T. Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity. Expert Opin. Ther. Pat. 13 (2003) 1545-1550
32. Vukovic V., and Tannock I.F. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br. J. Cancer 75 (1997) 1167-1172
33. Raghunand N., et al. Enhancement of chemotherapy by manipulation of tumour pH. Br. J. Cancer 80 (1999) 1005-1011
34. Teicher B.A., et al. A carbonic anhydrase inhibitor as a potential modulator of cancer therapies. Anticancer Res. 13 (1993) 1549-1556
35. Vullo D., et al. Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides - a new target for the design of antitumor and antiglaucoma drugs?. Bioorg. Med. Chem. Lett. 15 (2005) 963-969
36. Supuran C.T., et al. Carbonic anhydrase inhibitors: sulfonamides as antitumor agents?. Bioorg. Med. Chem. 9 (2001) 703-714
37. Xiang Y., et al. Acetazolamide inhibits aquaporin-1 protein expression and angiogenesis. Acta Pharmacol. Sin. 25 (2004) 812-816
38. Abbate F., et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 14 (2004) 217-223
39. Yokoi A., et al. Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Mol. Cancer Ther. 1 (2002) 275-286
40. Fukuoka K., et al. Mechanisms of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest. New Drugs 19 (2001) 219-227
41. Ozawa Y., et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur. J. Cancer 37 (2001) 2275-2282
42. Winum J.Y., et al. Carbonic anhydrase inhibitors. Synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with boron-containing sulfonamides, sulfamides, and sulfamates: toward agents for boron neutron capture therapy of hypoxic tumors. Bioorg. Med. Chem. Lett. 15 (2005) 3302-3306
43. Alterio V., et al. Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J. Am. Chem. Soc. 128 (2006) 8329-8335
44. Menchise V., et al. Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J. Med. Chem. 48 (2005) 5721-5727
45. Cecchi A., et al. Carbonic anhydrase inhibitors. Sulfonamides inhibit isozyme IX mediated acidification of hypoxic tumors. Fluorescent sulfonamides design as probes of membrane-bound carbonic anhydrase isozymes involvement in tumorigenesis. J. Med. Chem. 48 (2005) 4834-4841
46. Scozzafava A., et al. Carbonic anhydrase inhibitors: synthesis of membrane-impermeant, low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes. J. Med. Chem. 43 (2000) 292-300
47. Thiry A., et al. Indanesulfonamides as carbonic anhydrase inhibitors. Towards structure-based design of specific inhibitors of the tumor-associated isozyme CA IX. J. Med. Chem. 49 (2006) 2743-2749
48. Semenza G.L. Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol. Med. 7 (2001) 345-350